152 related articles for article (PubMed ID: 38462643)
21. Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations.
Bonifaz-Peña V; Contreras AV; Struchiner CJ; Roela RA; Furuya-Mazzotti TK; Chammas R; Rangel-Escareño C; Uribe-Figueroa L; Gómez-Vázquez MJ; McLeod HL; Hidalgo-Miranda A; Parra EJ; Fernández-López JC; Suarez-Kurtz G
PLoS One; 2014; 9(11):e112640. PubMed ID: 25419701
[TBL] [Abstract][Full Text] [Related]
22. Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China.
Jin T; Aikemu A; Zhang M; Geng T; Feng T; Kang L; Luo ML
Med Sci Monit; 2015 Dec; 21():3769-76. PubMed ID: 26632549
[TBL] [Abstract][Full Text] [Related]
23. Genetic Polymorphisms of Pharmacogenomic VIP Variants in the Circassian Subpopulation from Jordan.
Al-Eitan LN; Mohammad NN; Al-Maqableh HW; Hakooz NM; Dajani RB
Curr Drug Metab; 2019; 20(8):674-681. PubMed ID: 31362667
[TBL] [Abstract][Full Text] [Related]
24. Genetic Analysis of Pharmacogenomic VIP Variants of ABCB1, VDR and TPMT Genes in an Ethnically Isolated Population from the North Caucasus Living in Jordan.
Al-Eitan LN; Al-Maqableh HW; Mohammad NN; Hakooz NM; Dajani RB
Curr Drug Metab; 2020; 21(4):307-317. PubMed ID: 32368972
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenomic profile of a central European urban random population-Czech population.
Proietti R; Maranho Neto GA; Kunzova S; Lo Re O; Ahola-Olli A; Heliste J; Gonzalez-Rivas JP; Vinciguerra M
PLoS One; 2023; 18(4):e0284386. PubMed ID: 37079615
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China.
He Y; Yang H; Geng T; Feng T; Yuan D; Kang L; Luo M; Jin T
Int J Clin Exp Pathol; 2015; 8(10):13293-303. PubMed ID: 26722533
[TBL] [Abstract][Full Text] [Related]
27. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients.
Nakai K; Tsuboi J; Okabayashi H; Fukuhiro Y; Oka T; Habano W; Fukushima N; Nakai K; Obara W; Fujioka T; Suwabe A; Gurwitz D
Pharmacogenomics; 2007 Jul; 8(7):713-9. PubMed ID: 18240904
[TBL] [Abstract][Full Text] [Related]
28. Warfarin Dose and CYP2C Gene Cluster: An African Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African Patients.
Ndadza A; Cindi Z; Makambwa E; Chimusa E; Wonkam A; Kengne AP; Ntsekhe M; Dandara C
OMICS; 2019 Jan; 23(1):36-44. PubMed ID: 30566377
[TBL] [Abstract][Full Text] [Related]
29. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
30. Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes.
Muyambo S; Ndadza A; Soko ND; Kruger B; Kadzirange G; Chimusa E; Masimirembwa CM; Ntsekhe M; Nhachi CFB; Dandara C
OMICS; 2022 Jan; 26(1):35-50. PubMed ID: 34958284
[TBL] [Abstract][Full Text] [Related]
31. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
32. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
33. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
[TBL] [Abstract][Full Text] [Related]
34. Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.
Qayyum A; Najmi MH; Mansoor Q; Irfan M; Naveed AK; Hanif A; Kazmi AR; Ismail M
Clin Appl Thromb Hemost; 2018 Mar; 24(2):323-329. PubMed ID: 27879469
[TBL] [Abstract][Full Text] [Related]
35. Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses.
Di Fusco D; Ciccacci C; Rufini S; Forte V; Novelli G; Borgiani P
Thromb Res; 2013 Jul; 132(1):123-6. PubMed ID: 23726967
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetic landscape of pain management variants among Mediterranean populations.
Jmel H; Boukhalfa W; Gouiza I; Seghaier RO; Dallali H; Kefi R
Front Pharmacol; 2024; 15():1380613. PubMed ID: 38813106
[TBL] [Abstract][Full Text] [Related]
37. Characterization of ADME genes variation in Roma and 20 populations worldwide.
Škarić-Jurić T; Tomas Ž; Zajc Petranović M; Božina N; Smolej Narančić N; Janićijević B; Salihović MP
PLoS One; 2018; 13(11):e0207671. PubMed ID: 30452466
[TBL] [Abstract][Full Text] [Related]
38. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews.
Zhou Y; Lauschke VM
J Med Genet; 2018 Sep; 55(9):617-627. PubMed ID: 29970487
[TBL] [Abstract][Full Text] [Related]
40. Health influenced by genetics: A first comprehensive analysis of breast cancer high and moderate penetrance susceptibility genes in the Tunisian population.
Boujemaa M; Mighri N; Chouchane L; Boubaker MS; Abdelhak S; Boussen H; Hamdi Y
PLoS One; 2022; 17(3):e0265638. PubMed ID: 35333900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
